Oncoinvent ASA BRRGF
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 6.13M
- Market Cap
- —
- Volume/Avg
- — / 1
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 327.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://www.oncoinvent.com
Valuation
|
Metric
|
BRRGF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.76 |
Price/Sales | 327.16 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BRRGF
|
|---|---|
Quick Ratio | 2.43 |
Current Ratio | 2.43 |
Interest Coverage | — |
Quick Ratio
BRRGF
Profitability
|
Metric
|
BRRGF
|
|---|---|
Return on Assets (Normalized) | −103.41% |
Return on Equity (Normalized) | −147.73% |
Return on Invested Capital (Normalized) | −149.13% |
Return on Assets
BRRGF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^gbJYRY | LOCK|<!k!J | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|R>@?wf& | LOCK|?Dy@C | $84B | |||
| Moderna Inc
MRNA
| LOCK|tBC#X@ | LOCK|#zX | $81B | |||
| argenx SE ADR
ARGX
| LOCK|k!pM#J | LOCK|^!& | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#tPv><& | LOCK|xwj | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fYc<&?? | LOCK|j^^L | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s?BKFmlR | LOCK|P^>^ | $28B | |||
| Incyte Corp
INCY
| LOCK|#Pv#Bk | LOCK|&> | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|ZbL>>% | LOCK|h? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|P!d$>w> | LOCK|MT | $14B |
United States